+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Microbiome Partnering Terms and Agreements 2014 to 2019

  • ID: 4636692
  • Report
  • Region: Global
  • 130 pages
  • CurrentPartnering
1 of 5

FEATURED COMPANIES

  • 4D Pharma
  • Cornell University
  • German Cryo
  • Leiden University
  • OptiBiotix
  • Taconic Biosciences
  • MORE
The Global Microbiome Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in Microbiome partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Microbiome partnering contract documents
  • Top Microbiome deals by value
The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Microbiome deals since 2014. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2014. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products.

Report scope

Global Microbiome Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Microbiome trends and structure of deals entered into by leading companies worldwide.

Global Microbiome Partnering Terms and Agreements 2014 to 2019 includes:
  • Trends in Microbiome dealmaking in the biopharma industry since 2014
  • Analysis of Microbiome deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Microbiome deals
  • Access to over 130 Microbiome deal records and contract documents where available
  • The leading antibody deals by value since 2014
  • Most active Microbiome dealmakers since 2014
  • The leading Microbiome partnering resources
In Global Microbiome Partnering Terms and Agreements 2014 to 2019, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma
  • Cornell University
  • German Cryo
  • Leiden University
  • OptiBiotix
  • Taconic Biosciences
  • MORE
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Microbiome dealmaking
2.1. Introduction
2.2. Microbiome partnering over the years
2.3. Most active Microbiome dealmakers
2.4. Microbiome partnering by deal type
2.5. Microbiome partnering by therapy area
2.6. Microbiome partnering by industry sector
2.7. Deal terms for Microbiome partnering
2.7.1 Microbiome partnering headline values
2.7.2 Microbiome deal upfront payments
2.7.3 Microbiome deal milestone payments
2.7.4 Microbiome royalty rates
2.8. The anatomy of an Microbiome deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Microbiome deals
3.1. Introduction
3.2. Top Microbiome deals by value

Chapter 4 - Most active Microbiome dealmakers
4.1. Introduction
4.2. Most active Microbiome dealmakers
4.3. Most active Microbiome partnering company profiles

Chapter 5 - Microbiome contracts dealmaking directory
5.1. Introduction
5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Microbiome deals by company A-Z
Appendix 2 - Microbiome deals by stage of development
Appendix 3 - Microbiome deals by deal type
Appendix 4 - Microbiome deals by therapy area
Appendix 5 -Deal type definitions

Table of figures
Figure 1: Microbiome partnering since 2014
Figure 2: Active Microbiome dealmaking activity sincce 2014
Figure 3: Microbiome partnering by deal type since 2014
Figure 4: Microbiome partnering by disease type since 2014
Figure 5: Microbiome partnering by industry sector since 2014
Figure 6: Microbiome deals with a headline value
Figure 7: Microbiome deals with an upfront value
Figure 8: Microbiome deals with a milestone value
Figure 9: Microbiome deals with a royalty rate value
Figure 10: Top Microbiome deals by value since 2010
Figure 11: Most active Microbiome dealmakers since 2014
Figure 12: Microbiome partnering by technology type since 2014
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 4D Pharma
  • Cornell University
  • German Cryo
  • Leiden University
  • OptiBiotix
  • Taconic Biosciences
  • MORE
Global Microbiome Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of Microbiome deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Microbiome agreements with numerous real life case studies
  • Comprehensive access to Microbiome deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Microbiome deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Microbiome deals by value since 2014
  • Identify the most active Microbiome dealmakers since 2014
  • Detailed access to actual Microbiome contracts enter into by the leading big pharma and big biotech companies
  • Insight into the terms included in a Microbiome agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
5 of 5
  • 4D Pharma
  • Abbvie
  • ADL Bionatur Solutions
  • AIDS Clinical Trials Group
  • Alimentary Health
  • Allergan
  • Amag Pharmaceuticals
  • American Type Culture Collection (ATCC)
  • Assembly Biosciences
  • AstraZeneca
  • Azitra
  • Baylor College of Medicine
  • Baylor Miraca Genetics Laboratories
  • Bertin Pharma
  • Bill and Melinda Gates Foundation
  • Bio-Rad Laboratories
  • BIOASTER
  • Biocodex Microbiota Foundation
  • Biocore
  • Biomecite Diagnostics
  • Biomillenia
  • BiomX
  • Biosortia Pharmaceuticals
  • Boehringer Ingelheim
  • Boston University School of Medicine
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Cedars-Sinai Medical Center
  • Centers for Disease Control and Prevention
  • Centro Sperimentale del Latte
  • Children's Hospital Boston
  • Circuit Clinical
  • Clalit Health Services
  • Commense
  • Companion PBx
  • ConsortiaTX
  • CoreBiome
  • Cornell University
  • CosmosID
  • Crohn's and Colitis Foundation of America
  • CryoXtract
  • Dana-Farber Cancer Institute
  • DayTwo
  • DDL Diagnostic Laboratory
  • Dermala
  • Diversigen
  • DuPont Pioneer
  • Eagle Genomics
  • Emulate
  • EnBiotix
  • Enterome Bioscience
  • EpiBiome
  • Evelo Biosciences
  • Evogene
  • Evolve BioSystems
  • Evotec
  • ExeGi Pharma
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • Forsyth Institute
  • French National Institute for Agricultural Research
  • Galmed Pharmaceuticals
  • Genentech
  • General Automation Lab Technologies
  • Genetic Analysis
  • Genewiz
  • German Cryo
  • Ginkgo BioWorks
  • Glycosyn
  • Hackensack Meridian Health
  • Hamilton Company
  • Harvard School of Public Health
  • Harvard University
  • Helomics
  • HLH BioPharma Vertriebs
  • Holobiome
  • Human Longevity
  • Hy Laboratories
  • IBM
  • Innovate Biopharmaceuticals
  • Institute For Life Science Entrepreneurship (ILSE)
  • Institut Gustave Roussy
  • Intract Pharma
  • Intralytix
  • ISOThrive
  • Jackson Laboratory
  • Janssen Biotech
  • Janssen Human Microbiome Institute
  • Janssen Research & Development
  • Jennewein Biotechnologie
  • Johns Hopkins University
  • Johnson & Johnson Consumer Companies
  • Johnson & Johnson Innovation
  • JSR
  • Kaleido Biosciences
  • Karolinska Institute
  • Keio Gijuku University
  • Kenneth Rainin Foundation (KRF)
  • King's College Hospital
  • Kings College London
  • L'Oreal
  • Lawrence Livermore National Laboratory
  • Leiden University
  • Leidos
  • LNC
  • Locus Biosciences
  • MaaT Pharma
  • Massachusetts General Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical College of Wisconsin
  • Medical University of Graz
  • Memorial Sloan Kettering Cancer Center
  • Metabiomics
  • MetaboGen
  • Metabolon
  • Metagenics
  • Metanome
  • Microbiotica
  • Microsoft
  • MilliporeSigma
  • Monsanto
  • MyBiotics Pharma
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • National Psoriasis Foundation
  • Nestle Health Science
  • Norgen Biotek
  • North Zealand University Hospital
  • NuBiyota
  • Nutricion
  • Nutrilinea
  • NYU Langone Medical Center
  • One Codex
  • OpenBiome
  • OptiBiotix
  • Origin Biosciences
  • Owlstone Medical
  • Pfizer
  • Pharmabiota
  • Pharmatest Services
  • Prescient Medical
  • PureTech Health
  • Qiagen
  • Quark Venture
  • Quimica Europea
  • Rebiotix
  • Ritter Pharmaceuticals
  • Roswell Park Cancer Institute
  • SACCO
  • Salix Pharmaceuticals
  • SATT Lutech
  • Second Genome
  • Seres Therapeutics
  • Seven Bridges Genomics
  • Sirenas
  • Stanford Cancer Institute
  • Stanford University School of Medicine
  • Symbiotix Biotherapies
  • Synlogic
  • Synthetic Biologics
  • Taconic Biosciences
  • Takeda Pharmaceutical
  • Tata Chemicals
  • Texas Children’s Hospital
  • The BioCollective
  • The Parker Institute For Cancer Immunotherapy
  • Tsinghua University
  • uBiome
  • University College Cork
  • University of Adelaide
  • University of Alberta
  • University of British Columbia
  • University of Buffalo
  • University of California
  • San Diego
  • University of California
  • San Diego (UCSD) School of Medicine
  • University of California Irvine
  • University of Chicago
  • University of Cincinnati
  • University of Heidelberg
  • University of Maryland Ventures
  • University of Nebraska
  • University of Pennsylvania
  • University of Rhode Island
  • University of South Alabama (USA) Mitchell Cancer Institute
  • University of Texas
  • Vedanta Biosciences
  • Venture Life
  • Vertex Pharmaceuticals
  • Viome
  • Washington University in St Louis
  • Weizmann Institute
  • Xycrobe Therapeutics
  • Yeda Research and Development Company
  • Yili Industrial Group
  • Zymo Research
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll